Does verapamil increase the survival of patients with anthracycline-resistant metastatic breast carcinoma?
This clinical trial demonstrates that a chemosensitizer, such as VER, can increase the survival of MBC patients with acquired anthracycline resistance.
Patients with poor life expectancy progressed more than the matched surviving patients, when measured from an initially similar position, despite better IOP control.